Assessment of Safety of GlaxoSmithKline (GSK) Vaccines' Quadrivalent Seasonal Influenza Vaccine, Fluarix Tetra When Administered According to the Approved Prescribing Information in Korea.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 14 Mar 2017
At a glance
- Drugs GSK 2321138A (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 09 Mar 2017 Planned End Date changed from 1 Mar 2020 to 1 Jun 2020.
- 03 Mar 2017 Status changed from not yet recruiting to active, no longer recruiting.
- 04 Oct 2016 Planned End Date changed from 1 Dec 2021 to 1 Mar 2020.